CLIFF (Cordlife Group) ROCE %: -3.93% (As of Mar. 2026)

What is Cordlife Group ROCE %?

Cordlife Group CLIFF 33 ROCE % is -3.93% as of Mar. 2026. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cordlife Group's annualized ROCE % for the quarter that ended in Mar. 2026 was -3.93%.

Cordlife Group (OTCPK:CLIFF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cordlife Group ROCE % Related Terms

Cordlife Group ROCE % Historical Data

* Premium members only.

The historical data trend for Cordlife Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cordlife Group ROCE % Chart

Cordlife Group Annual Data

Trend

Jun15

Jun16

Jun17

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

3.42

2.73

2.22

-9.51

-6.15

Cordlife Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-3.46	-5.93	-5.14	-9.69	-3.93

33GF Score

Cordlife Group Ltd CLIFF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cordlife Group ROCE % Calculation

Cordlife Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-8.404	/	( ( (160.798 - 21.423)	+	(156.318 - 22.419) )	/ 2 )
	=	-8.404	/	( (139.375	+	133.899)	/ 2 )
	=	-8.404	/	136.637
	=	-6.15 %

Cordlife Group's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-5.236	/	( ( (156.318 - 22.419)	+	(156.672 - 24.359) )	/ 2 )
	=	-5.236	/	( ( 133.899	+	132.313 )	/ 2 )
	=	-5.236	/	133.106
	=	-3.93 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -3.93% mean?

Cordlife Group (CLIFF) has a ROCE % of -3.93% as of Mar. 2026.

Is Cordlife Group's ROCE % too high?

Cordlife Group's current ROCE % is -3.93%. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Cordlife Group's ROCE % compare to TMO and DHR?

Cordlife Group's ROCE % of -3.93% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Diagnostics & Research company?

A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Cordlife Group's current ROCE % is -3.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cordlife Group stock overvalued right now?

Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current ROCE % is -3.93%. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current ROCE % is -3.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cordlife Group (CLIFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued. The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08. GuruFocus considers Cordlife Group to be Significantly Overvalued.

Key valuation signals for CLIFF:

ROCE %: -3.93%
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cordlife Group Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies SGX:505 SGX:1H3 SGX:1B1 SGX:8YY TMO DHR SHSE:603259 XSWX:LONN IDXX A WAT NTRA IQV ILMN MTD DGX LH GH MEDP XPAR:ERF

Other Exchanges P8A:Singapore

Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994

Website https://www.cordlife.com

Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.

33GF Score

Get the complete analysis for CLIFF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15

Price

$0.08

GF Value

View CLIFF Analysis

See ROCE % data for all stocks →